| DESCRIPTION | - E.A. EISENHAUER et al., "New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1.", Eur. J of Cancer, (20090000), vol. 45, pages 228 - 247 | - |
| DESCRIPTION | - E.A. EISENHAUER et al., "New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1.", Eur. J. of Cancer, (20090000), vol. 45, pages 228 - 247 | - |
| DESCRIPTION | - Lancet Oncol, vol. 15, no. 8, pages 852 - 61 | - |
| DESCRIPTION | - LEDERMANN et al., New England Journal of Medicine, (20120000), vol. 366, page 15 | - |
| DESCRIPTION | - N Engl J Med, (20120000), vol. 366, no. 15, pages 1382 - 1392 | - |
| DESCRIPTION | - "Parp Inhibitors and Cancer Therapy. Curtin N.", Poly ADP Ribosylation, Lands Bioscience and Springer Bioscience, (20060000), pages 218 - 233 | - |
| DESCRIPTION | - PFISTERER, J.M. PLANTEI. VERGOTEA. DU BOISH. HIRTEA. J. LACAVEU. WAGNERA. STAHLEG. STUARTR. KIMMIG, "Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG", J Clin Oncol, (20060000), vol. 24, no. 29, pages 4699 - 4707 | - |
| DESCRIPTION | - RUSTIN et al., Int J Gynecol Cancer, (20110000), vol. 21, pages 419 - 423 | - |
| DESCRIPTION | - S. M. BERGE et al., J. Pharmaceutical Sciences, (19770000), vol. 66, pages 1 - 19 | - |
| DESCRIPTION | - TCGA, "Integrated genomic analyses of ovarian carcinoma", Nature, (20110000), vol. 474, no. 7353, pages 609 - 615 | - |
| DESCRIPTION | - DANN RBDELOIA JATIMMS KMZORN KKPOTTER JFLAKE DD 2NDLANCHBURY JSKRIVAK TC, "BRCA 1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer", Gynecol Oncol, (20120000), vol. 125, no. 3, doi:10.1016/j.ygyno.2012.03.006, pages 677 - 82, XP028488681 | |
| DESCRIPTION | - TURNER, N.A. TUTTA. ASHWORTH, "Hallmarks of 'BRCAness' in sporadic cancers", Nat. Rev. Cancer, (20040000), vol. 4, no. 10, doi:10.1038/nrc1457, pages 814 - 9, XP055085873 | |
| DESCRIPTION | - POPOVA et al., "Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation", CANCER RES, (20120000), vol. 72, doi:10.1158/0008-5472.CAN-12-1470, pages 5454 - 5462, XP055341888 | |
| DESCRIPTION | - HENNESSY, B. T. et al., "Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer", Journal of clinical oncology: official journal of the American Society of Clinical Oncology, (20100000), vol. 28, doi:10.1200/JCO.2009.27.2997, pages 3570 - 3576, XP055070076 | |
| INTERNATIONAL-SEARCH-REPORT | - AUDEH, "Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition", Pharmgenomics Pers Med October, (20140000), vol. 7, pages 307 - 316, XP055451834 [X] 1-7 * . Especially pg 310 col 1 para 4, pg 312 col 1 para 2, pg 313 col 2 para 2. * [Y] 22, 82 | |
| OPPOSITION | - Adams Ben, "Tesaro’s PARP ovarian cancer drug hits PhIII goal; prepares to file", Fierce Biotech, (20160629), pages 1 - 2, Fierce Biotech, URL: https://www.fiercebiotech.com/biotech/tesaro-s-parp-ovarian-cancer-drug-hits-phiii-goal-prepares-to-file, (20241205), XP093231599 | - |
| OPPOSITION | - Anonymous, "A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer", Clinical Trials.gov, NCT01847274, (20230602), pages 1 - 19, XP093232179 | - |
| OPPOSITION | - Anonymous, "Assessment report Zejula International non-proprietary name: niraparib Procedure No. EMEA/H/C/004249/0000", EUROPEAN MEDICINES AGENCY, (20170914), pages 1 - 122, XP093232174 | - |
| OPPOSITION | - Anonymous, "myChoice HRD(TM) Test Identifies Breast Cancer Patients Likely to Respond to Platinum-Containing Therapies", myriad, (20151210), myriad, URL: https://myriad.gcs-web.com/static-files/52c1eb87-b563-443a-a8d9-17fa04bf2e95, XP093231425 | - |
| OPPOSITION | - Anonymous, "Niraparib", Tesarobio, (20160622), pages 1 - 4, Tesarobio, URL: https://web.archive.org/web/20160622232504/http://www.tesarobio.com:80/niraparib, (20241205), XP093231617 | - |
| OPPOSITION | - Anonymous, "OLAPARIB - MEDICAL REVIEW(S) - APPLICATION NUMBER: 206162Orig1s000", CENTER FOR DRUG EVALUATION AND RESEARCH, (20150101), XP093231378 | - |
| OPPOSITION | - Anonymous, "TESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer in Both Cohorts of the Phase 3 NOVA Trial", Tesaro, (20160601), pages 1 - 3, XP093231595 | - |
| OPPOSITION | - Anonymous, "Treatment of HRD-Negative Ovarian Cancer", (20191024), URL: https://www.onclive.com/view/treatment-of-hrd-negative-ovarian-cancer, XP093222701 | - |
| OPPOSITION | - Anonymous, "Zejula International non-proprietary name: niraparib", Assessment report EMA - Procedure No. EMEA/H/C/004249/0000, European Medicines Agency, GB, GB , (20170914), pages 1 - 122, XP009527811 | - |
| OPPOSITION | - Bradley J. Monk, Robert L. Coleman, "Role of PARP Inhibitors in Advanced Ovarian Cancer", (20230530), URL: https://www.onclive.com/view/role-of-parp-inhibitors-in-advanced-ovarian-cancer, XP093222693 | - |
| OPPOSITION | - Tesaro, Inc., "NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer", ClinicalTrials.gov, NLM, (20141223), pages 1 - 23, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT01847274?cond=NCT01847274&rank=1&tab=history&a=28#version-content-panel, XP093222714 | - |
| OPPOSITION | - Tesaro, Inc., "NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer", ClinicalTrials.gov, NLM, (20160511), pages 1 - 17, ClinicalTrials.gov, URL: https://clinicaltrials.gov/study/NCT01847274?cond=NCT01847274&rank=1&tab=history&a=32#version-content-panel, XP093222711 | - |
| OPPOSITION | - Timms Kirsten M, Neff Christopher, Abkevich Victor, Jones Joshua T, Kolquist Kathryn, Mirza Michael, Lanchbury Jerry S, Mikule Keith, Agarwal Shefali, Hartman Anne-Renee, Guti Alexander, Wilcoxen Keith, "DNA repair defi ciencies in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA study", European Cancer Congress (ECC 2015); Vienna, Austria, ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE, (20150926), pages 1 - 1, XP093222719 | - |
| OPPOSITION | - Timms K., Neff C., Abkevich V., Jones J.T., Kolquist K.A., Mirza M., Lanchbury J., Mikule K., Agarwal S., Hartman A.R., Gutin A., Wilcoxen K., "458 DNA repair deficiencies in ovarian cancer: Genomic analysis of high grade serous ovarian tumors from the NOVA study", Poster presented at ESMO, (20150926), pages 1 - 1, XP093231604 | - |
| OPPOSITION | - Akay Melek, Funingana Ionut-Gabriel, Patel Grisma, Mustapha Rami, Gjafa Ernese, Ng Tony, Ng Kenrick, Flynn Michael J., "An In-Depth Review of Niraparib in Ovarian Cancer: Mechanism of Action, Clinical Efficacy and Future Directions", Oncology and Therapy, (20211201), vol. 9, no. 2, doi:10.1007/s40487-021-00167-z, ISSN 2366-1070, pages 347 - 364, XP093222680 | |
| OPPOSITION | - Ngoi N.Y.L., Tan D.S.P., "The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?", ESMO open : cancer horizons, European Society for Medical Oncology, London, London , (20210601), vol. 6, no. 3, doi:10.1016/j.esmoop.2021.100144, ISSN 2059-7029, pages 100144 - 12, XP093222676 | |
| OPPOSITION | - N. Y. L. Ngoi, "The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?", Esmo Open Cancer Horizons, (2021), vol. 6, doi:10.1016/j.esmoop.2021.100144, XP093222676 | |
| OPPOSITION | - Haluska P; Timms K M; AlHilli M; Wang Y; Hartman A M; Jones J; Gutin A; Sangale Z; Neff C; Lynchbury J; Rudolph-Owen L; Becker M A; Agarwal S; Wilcoxen K M, "Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer", European Journal of Cancer, Elsevier, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona, Spain, (20141031), vol. 50, no. Suppl. 6, doi:10.1016/S0959-8049(14)70340-5, ISSN 0959-8049, pages 72 - 73, XP009505142 | |
| OPPOSITION | - Karen A Gelmon; Marc Tischkowitz; Helen Mackay; Kenneth Swenerton; André Robidoux; Katia Tonkin; Hal Hirte; David Huntsman; Mark Clemons; Blake Gilks; Rinat Yerushalmi; Euan Macpherson; James Carmichael; Amit Oza, "Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20110901), vol. 12, no. 9, doi:10.1016/S1470-2045(11)70214-5, pages 852 - 861, XP009521893 | |
| OPPOSITION | - Telli Melinda L., " PARP inhibitors in cancer: moving beyond BRCA", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20110901), vol. 12, no. 9, doi:10.1016/S1470-2045(11)70237-6, ISSN 1470-2045, pages 827 - 828, XP093231437 | |
| OPPOSITION | - Shahneen K Sandhu et al, "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20130801), vol. 14, no. 9, doi:10.1016/S1470-2045(13)70240-7, pages 882 - 892, XP055407449 | |
| OPPOSITION | - Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin, Nathan Kreischer, Khin Thway, Heidrun Gevensleben, Linda Sun, John Loughney, Manash Chatterjee, Carlo Toniatti, Christopher L Carpenter, Robert Iannone, Stan B Kaye, Johann S De Bono, Robert M Wenham, "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", The Lancet Oncology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20130801), vol. 14, no. 9, doi:10.1016/S1470-2045(13)70240-7, pages 882 - 892, XP055407449 | |
| OPPOSITION | - Jones Philip, Wilcoxen Keith, Rowley Michael, Toniatti Carlo, "Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination", Journal of Medicinal Chemistry, American Chemical Society, US, US , (20150423), vol. 58, no. 8, doi:10.1021/jm5018237, ISSN 0022-2623, pages 3302 - 3314, XP055855855 | |
| OPPOSITION | - Drew Yvette, "The development of PARP inhibitors in ovarian cancer: from bench to bedside", British Journal of Cancer, Nature Publishing Group UK, London, London, (20151215), vol. 113, no. Suppl 1, doi:10.1038/bjc.2015.394, ISSN 0007-0920, pages S3 - S9, XP037796159 | |
| OPPOSITION | - Ledermann Jonathan A; El-Khouly Fatima, "PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions", British Journal of Cancer, Nature Publishing Group UK, London, London, (20151215), vol. 113, no. Suppl 1, doi:10.1038/bjc.2015.395, ISSN 0007-0920, pages S10 - S16, XP037796156 | |
| OPPOSITION | - TURNER NICHOLAS C ET AL, "A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor", The EMBO journal / European Molecular Biology Organization, IRL Press, Oxford, Oxford , (20080501), vol. 27, no. 9, doi:10.1038/emboj.2008.61, ISSN 0261-4189, pages 1368 - 1377, XP002498071 | |
| OPPOSITION | - S. Postel-Vinay, "A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer", Oncogene, (20130812), vol. 32, doi:10.1038/onc.2013.311, XP037750554 | |
| OPPOSITION | - Sehouli J., Braicu E., Chekerov R., "PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives", GEBURTSHILFE UND FRAUENHEILKUNDE, Georg Thieme Verlag, DE, DE , vol. 76, no. 02, doi:10.1055/s-0035-1558185, ISSN 0016-5751, pages 164 - 169, XP093231380 | |
| OPPOSITION | - Jonathan Ledermann, Philipp Ledermann, Charlie Harter, Michael Gourley, Ignace Friedlander, Gordon Vergote, Clare Rustin, Werner Scott, Ronnie Meier, Tamar Shapira Frommer, Daniela Safra, Euan Matei, Claire Macpherson, James Watkins, Ursula Carmichael, Matulonis, "Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer", New England Journal of Medicine, New England Journal of Medicine, (20120412), vol. 366, no. 15, doi:10.1056/NEJMoa1105535, ISSN 00284793, pages 1382 - 1392, XP055075393 | |
| OPPOSITION | - Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa E. Ben-Baruch, Christian Marth, RadosÅ‚aw MÄ…dry, René D. Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas Du Bois, Antonio González-MartÃn, Philippe Follana, Benedict Benigno, Per Rosenberg, Lucy Gilbert, Bobbie J. Rimel, Joseph Buscema, John P. Balser, Shefali Agarwal, Ursula A. Matulonis, "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer", The New England journal of medicine, Massachusetts Medical Society, US, US , (20161201), vol. 375, no. 22, doi:10.1056/NEJMoa1611310, ISSN 0028-4793, pages 2154 - 2164, XP055567829 | |
| OPPOSITION | - Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa E. Ben-Baruch, Christian Marth, RadosÅ‚aw MÄ…dry, René D. Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas Du Bois, Antonio González-MartÃn, Philippe Follana, Benedict Benigno, Per Rosenberg, Lucy Gilbert, Bobbie J. Rimel, Joseph Buscema, John P. Balser, Shefali Agarwal, Ursula A. Matulonis, "Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer", The New England journal of medicine, US , (20161201), vol. 375, no. 22, doi:10.1056/NEJMoa1611310, ISSN 0028-4793, pages 2154 - 2164, XP055567829 | |
| OPPOSITION | - Mirza M.R., Monk B.J., Ledermann J.A., Oza A.M., Del Campo J.M., Berek J.S., Mahner S., Wenham R.M., Vergote I.B., Fabbro M., Marth C., Dørum A., Lorusso D., Katsaros D., Bruchim I., Malander S., Herrstedt J., Agarwal S., Martell R.E., Matulonis U., "Engot-Ov16/Nova: a Phase 3 Randomized Double-Blind Trial of Maintenance with Parp-Inhibitor Niraparib Versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer", Annals of Oncology, Elsevier, (20140901), vol. 25, no. Suppl. 4, doi:10.1093/annonc/mdu338.65, ISSN 0923-7534, page iv325, XP093222689 | |
| OPPOSITION | - Kaye S.B., "Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 years", Annals of Oncology, Elsevier, (20160401), vol. 27, doi:10.1093/annonc/mdw082, ISSN 0923-7534, pages i1 - i3, XP093231382 | |
| OPPOSITION | - Ledermann J.A., "PARP inhibitors in ovarian cancer", Annals of Oncology, Elsevier, (20160401), vol. 27, doi:10.1093/annonc/mdw094, ISSN 0923-7534, pages i40 - i44, XP093231420 | |
| OPPOSITION | - J. Murai et al, "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors", Cancer research, American Association for Cancer Research, (20121101), vol. 72, no. 21, doi:10.1158/0008-5472.CAN-12-2753, ISSN 00085472, pages 5588 - 5599, XP055094093 | |
| OPPOSITION | - J. Murai, S.-Y. N. Huang, B. B. Das, A. Renaud, Y. Zhang, J. H. Doroshow, J. Ji, S. Takeda, Y. Pommier, "Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors", Cancer research, American Association for Cancer Research, (20121101), vol. 72, no. 21, doi:10.1158/0008-5472.CAN-12-2753, ISSN 00085472, pages 5588 - 5599, XP055094093 | |
| OPPOSITION | - Hilli Mariam Al, Weroha S. John, Becker Marc, Hou Xiaonan, Harrington Sean, Mckinstrey Sarah, Kalli Kimberly, Goodman Karin, Wilcoxen Keith, Swisher Elizabeth, Kaufmann Scott, Haluska Paul, "Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer", Clinical Cancer Research, Association for Cancer Research, US, US, (20131001), vol. 19, no. 19_Supplement, doi:10.1158/1078-0432.OVCA13-PR05, ISSN 1078-0432, pages PR05 - PR05, XP093231391 | |
| OPPOSITION | - Euan A. Stronach, James Paul, Kirsten M. Timms, Elisha Hughes, Krystal Brown, Christopher Neff, Michael Perry, Alexander Gutin, Mona El-Bahrawy, Jennifer H. Steel, Xinxue Liu, Liz-Anne Lewsley, Nadeem Siddiqui, Hani Gabra, Jerry S. Lanchbury, Robert Brown, "Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy", MOLECULAR CANCER RESEARCH, American Association for Cancer Research, US, US , (20180701), vol. 16, no. 7, doi:10.1158/1541-7786.MCR-18-0034, ISSN 1541-7786, pages 1103 - 1111, XP055539341 | |
| OPPOSITION | - Konstantinopoulos Panagiotis A., Ceccaldi Raphael, Shapiro Geoffrey I., D'andrea Alan D., "Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer", CANCER DISCOVERY, American Association for Cancer Research, US, US , (20151101), vol. 5, no. 11, doi:10.1158/2159-8290.CD-15-0714, ISSN 2159-8274, pages 1137 - 1154, XP093222683 | |
| OPPOSITION | - Shaojun Zhang, Yuan Yuan, Hao Dapeng, Chaudhuri Gautam, "A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy", PLoS ONE, Public Library of Science, (20141201), vol. 9, no. 12, doi:10.1371/journal.pone.0113169, page e113169, XP055418698 | |
| OPPOSITION | - Symeonides Stefan, Gourley Charlie, "Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge", Frontiers in Oncology, Frontiers Media S.A., vol. 5, doi:10.3389/fonc.2015.00229, ISSN 2234-943X, XP093231389 | |
| OPPOSITION | - How Jeffrey A., Jazaeri Amir A., Fellman Bryan, Daniels Molly S., Penn Suzanna, Solimeno Cara, Yuan Ying, Schmeler Kathleen, Lanchbury Jerry S., Timms Kirsten, Lu Karen H., Yates Melinda S., "Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer", Cancers, MDPI AG, CH, CH , (20210301), vol. 13, no. 5, doi:10.3390/cancers13050946, ISSN 2072-6694, pages 946 - 17, XP093222679 | |
| OPPOSITION | - Konstantinopoulos Panagiotis A, Matulonis Ursula A, "BRCA status in epithelial ovarian cancer: implications for management and future clinical trial design", Clinical Investigation, Future Science, UK, UK , (20130801), vol. 3, no. 8, doi:10.4155/cli.13.55, ISSN 2041-6792, pages 777 - 790, XP093222682 | |
| SEARCH | - SHAHNEEN K SANDHU ET AL, "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial", THE LANCET ONCOLOGY, AMSTERDAM, NL, (20130801), vol. 14, no. 9, doi:10.1016/S1470-2045(13)70240-7, ISSN 1470-2045, pages 882 - 892, XP055407449 [X] 1-27 * tables 2-5 * | |
| SEARCH | - JONATHAN LEDERMANN ET AL, "Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer", NEW ENGLAND JOURNAL OF MEDICINE, (20120412), vol. 366, no. 15, doi:10.1056/NEJMoa1105535, ISSN 0028-4793, pages 1382 - 1392, XP055075393 [X] 1-27 * Background, Discussion.; figure 1 * | |
| SEARCH | - SHAOJUN ZHANG ET AL, "A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy", PLOS ONE, (20141201), vol. 9, no. 12, doi:10.1371/journal.pone.0113169, page e113169, XP055418698 [X] 1-27 * page e113178 * | |
